Showing results (61-70 of 93) with videos related to

Sort By:
Pageof 10
Journal of Clinical Pharmacology|February 24, 2006
Effects of ezetimibe on cyclosporine pharmacokinetics in healthy subjectsArthur J Bergman, Joanne Burke, Patrick Larson, et al.
BMC Cardiovascular Disorders|April 22, 2021
Health-related quality of life in patients with recurrent pericarditis: results from a phase 2 study of rilonaceptDavid Lin, Allan Klein, David Cella, et al.
European Heart Journal. Cardiovascular Imaging|August 22, 2024
Longitudinal cardiac magnetic resonance imaging following clinical response to rilonacept and prior to recurrence upon treatment suspension: a RHAPSODY subgroup analysisPaul C Cremer, Antonio Brucato, Antonella Insalaco, et al.
Journal of Clinical Lipidology|February 5, 2011
Effects of a niacin receptor partial agonist, MK-0354, on plasma free fatty acids, lipids, and cutaneous flushing in humansEseng Lai, M Gerard Waters, James R Tata, et al.
International Journal of Clinical Practice|January 27, 2009
Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemiaD Maccubbin, H E Bays, A G Olsson, et al.
CJC Open|July 18, 2024
Absence of Pericarditis Recurrence in Rilonacept-Treated Patients With COVID-19 and SARS-CoV-2 Vaccination: Results From the RHAPSODY Long-term ExtensionAntonio Brucato, Lucia Trotta, Michael Arad, et al.
JACC. Basic to Translational Science|March 5, 2021
The Role of NLRP3 Inflammasome in Pericarditis: Potential for Therapeutic ApproachesAdolfo G Mauro, Aldo Bonaventura, Alessandra Vecchié, et al.
Chest|July 28, 2020
Clinical Presentation and Outcomes of Acute Pericarditis in a Large Urban Hospital in the United States of AmericaAlessandra Vecchié, Juan G Chiabrando, Megan S Dell, et al.
The New England Journal of Medicine|November 17, 2020
Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent PericarditisAllan L Klein, Massimo Imazio, Paul Cremer, et al.
Heart (British Cardiac Society)|October 31, 2022
Transition to rilonacept monotherapy from oral therapies in patients with recurrent pericarditisAntonio Brucato, Alistair Wheeler, Sushil Allen Luis, et al.
Pageof 10